Extract to table
Pull the structured facts out of a document: parties, dates, amounts, obligations.
Extract to table / memo-thorngate-preliminary-valuation-summary.docx
memo-thorngate-preliminary-valuation-summary.docx
Parties
HARKNESS LLP
Penterra Pharmaceuticals Corp
Thorngate Partners LLC
Net Inc
Whitfield Graves LLP
Crowne Albany Services Inc
Dates
August 4, 2023
June 2, 2023
August 3, 2023
June 16, 2023
June 15, 2023
June 14, 2023
July 19, 2023
March 31, 2023
June 1, 2023
May 28, 2023
Amounts
$2,500,000
$1,250,000
$500,000
$78.4
$112.6
$347
$680
$42
$1.836
$412
Obligations
These factors must be analyzed carefully to ensure that the CVR is appropriately valued and that the total consideration (upfront plus CVR) fairly reflects the value of Caliston
However, this incremental value is highly speculative given the preclinical status of both compounds and the substantial clinical, regulatory, and commercial risks that must be overcome before either compound could generate revenue